Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Unfractionated formalinized allergoid is a chemically modified allergen extract used in allergen immunotherapy (AIT) for the treatment of allergic diseases such as grass pollen allergy. Allergoids are produced by polymerizing native allergen extracts with aldehydes, most commonly formaldehyde. This process reduces the ability of the allergens to induce IgE-mediated hypersensitivity (allergenicity) while preserving or enhancing their capacity to induce immune tolerance and blocking antibody responses. The chemical modification involves covalent cross-linking between protein molecules, primarily through reaction with primary amines such as lysine residues, resulting in high-molecular-weight polymers that are less likely to trigger immediate allergic reactions but still stimulate regulatory T cell responses and production of protective antibodies like IgG4. Unfractionated refers to the use of these polymerized extracts without further size-based separation or purification steps[2][3][6][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on unfractionated formalinized allergoid.